1
|
Preux C, Bertin M, Tarot A, Authier N, Pinol N, Brugnon D, Pereira B, Guastella V. Prevalence of Opioid Use Disorder among Patients with Cancer-Related Pain: A Systematic Review. J Clin Med 2022; 11:jcm11061594. [PMID: 35329919 PMCID: PMC8954099 DOI: 10.3390/jcm11061594] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 03/03/2022] [Accepted: 03/10/2022] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND The opioid use disorder is an international public health problem. Over the past 20 years it has been the subject of numerous publications concerning patients treated for chronic pain other than cancer-related. Patients with cancer-related pain are also at risk of opioid use disorder. The primary objective of this literature review was to determine the prevalence of opioid use disorder in patients with cancer-related chronic pain. Its secondary objective was to identify the characteristics of these opioid users. METHODS This is a literature review of studies published over the last twenty years, from 1 January 2000 to 31 December 2020 identified by searching the three main medical databases: Pubmed, Cochrane, and Embase. A meta-analysis took account of between and within-study variability with the use of random-effects models estimated by the DerSimonian and Laird method. RESULTS The prevalence of opioid use disorder was 8% (1-20%) and of the risk of use disorder was 23.5% (19.5-27.8%) with I2 values of 97.8% and 88.7%, respectively. CONCLUSIONS Further studies are now needed on the prevalence of opioid use disorder in patients treated for cancer-related chronic pain. A screening scale adapted to this patient population is urgently needed.
Collapse
Affiliation(s)
- Céline Preux
- Palliative Care Center, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France; (C.P.); (M.B.); (A.T.); (D.B.)
| | - Marion Bertin
- Palliative Care Center, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France; (C.P.); (M.B.); (A.T.); (D.B.)
| | - Andréa Tarot
- Palliative Care Center, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France; (C.P.); (M.B.); (A.T.); (D.B.)
| | - Nicolas Authier
- Neuro-Dol, Service Pharmacologie Médicale, Centres d’Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, CHU Clermont-Ferrand, Université de Clermont Auvergne, F-63001 Clermont-Ferrand, France;
- Institut Analgésia, Faculté de Médecine, BP38, F-63001 Clermont-Ferrand, France
- Observatoire Français des Médicaments Antalgiques/French Monitoring Centre for Analgesic Drugs, Université Clermont-Ferrand, F-63001 Clermont-Ferrand, France
| | - Nathalie Pinol
- Centre de Documentation et Recherche de la Faculté de Médecine, CHU Clermont-Ferrand, Université de Clermont Auvergne, F-63000 Clermont-Ferrand, France;
| | - David Brugnon
- Palliative Care Center, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France; (C.P.); (M.B.); (A.T.); (D.B.)
| | - Bruno Pereira
- Unité de Biostatistiques, Direction de la Recherche Clinique et de l’Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France;
| | - Virginie Guastella
- Palliative Care Center, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France; (C.P.); (M.B.); (A.T.); (D.B.)
- Neuro-Dol, Service Pharmacologie Médicale, Centres d’Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, CHU Clermont-Ferrand, Université de Clermont Auvergne, F-63001 Clermont-Ferrand, France;
- Correspondence: ; Tel.: +33-46-7367-506960
| |
Collapse
|
2
|
Lau J, Mazzotta P, Fazelzad R, Ryan S, Tedesco A, Smith AJ, Sud A, Furlan AD, Zimmermann C. Assessment tools for problematic opioid use in palliative care: A scoping review. Palliat Med 2021; 35:1295-1322. [PMID: 34000897 PMCID: PMC8267087 DOI: 10.1177/02692163211015567] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Screening for problematic opioid use is increasingly recommended in patients receiving palliative care. AIM To identify tools used to assess for the presence or risk of problematic opioid use in palliative care. DESIGN Scoping review. DATA SOURCES Bibliographic databases (inception to January 31, 2020), reference lists, and grey literature were searched to find primary studies reporting on adults receiving palliative care and prescription opioids to manage symptoms from advanced cancer, neurodegenerative diseases, or end-stage organ diseases; and included tools to assess for problematic opioid use. There were no restrictions based on study design, location, or language. RESULTS We identified 42 observational studies (total 14,431 participants) published between 2009 and 2020 that used questionnaires (n = 32) and urine drug tests (n = 21) to assess for problematic opioid use in palliative care, primarily in US (n = 38) and outpatient palliative care settings (n = 36). The questionnaires were Cut down, Annoyed, Guilty, and Eye-opener (CAGE, n = 8), CAGE-Adapted to Include Drugs (CAGE-AID, n = 6), Opioid Risk Tool (n = 9), Screener and Opioid Assessment for Patients with Pain (SOAPP; n = 3), SOAPP-Revised (n = 2), and SOAPP-Short Form (n = 5). Only two studies' primary objectives were to evaluate a questionnaire's psychometric properties in patients receiving palliative care. There was wide variation in how urine drug tests were incorporated into palliative care; frequency of abnormal urine drug test results ranged from 8.6% to 70%. CONCLUSION Given the dearth of studies using tools developed or validated specifically for patients receiving palliative care, further research is needed to inform clinical practice and policy regarding problematic opioid use in palliative care.
Collapse
Affiliation(s)
- Jenny Lau
- Division of Palliative Care, University of Toronto, Toronto, ON, Canada
- Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada
- Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Paolo Mazzotta
- Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada
- Temmy Latner Centre for Palliative Care, Sinai Health System, Toronto, ON, Canada
| | - Rouhi Fazelzad
- UHN Library and Information Services, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Suzanne Ryan
- Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
- Division of Palliative Medicine, University of Toronto, Toronto, ON, Canada
| | - Alissa Tedesco
- Temmy Latner Centre for Palliative Care, Sinai Health System, Toronto, ON, Canada
| | - Andrew J. Smith
- Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada
| | - Abhimanyu Sud
- Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada
- Medical Psychiatry Alliance, Toronto, ON, Canada
| | - Andrea D. Furlan
- Division of Physical Medicine and Rehabilitation, Department of Medicine, University of Toronto, Toronto, ON, Canada
- Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada
- Institute for Work and Health, Toronto, ON, Canada
| | - Camilla Zimmermann
- Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
- Division of Palliative Medicine, University of Toronto, Toronto, ON, Canada
- Division of Medical Oncology, University of Toronto, Toronto, ON, Canada
| |
Collapse
|